when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
calendar
approval

approval

CYLTEZO (ADALIMUMAB-ADBM) — FDA approval

May 20, 2025CYLTEZOupdated 5mo ago

community read0 votes

Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION

view source ↗

Data sources

last refreshed 5mo ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

drug timeline · 8

approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalOct 16, 2025 · 350d ago
approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalApr 30, 2024 · 884d ago
approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalJul 19, 2023 · 1170d ago
approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalJun 30, 2023 · 1189d ago
approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMay 18, 2023 · 1232d ago
approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMar 22, 2023 · 1289d ago
approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalOct 3, 2022 · 1459d ago
approvalCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalMar 18, 2022 · 1658d ago

same company · ±60 days · 2

approvalspesolimab: SPEVIGO (SPESOLIMAB-SBZO) — FDA approvalMay 28, 2025
approvalspesolimab: SPEVIGO (SPESOLIMAB-SBZO) — FDA approvalMay 28, 2025

🐶 often sniffed alongside

top 7

tagApproval48 co-mentions · 12 sources
drugHUMIRA48 co-mentions · 12 sources
companyBoehringer Ingelheim Corp24 co-mentions · 12 sources
drugABRILADA24 co-mentions · 12 sources
drugYUSIMRY24 co-mentions · 12 sources
drugAMJEVITA24 co-mentions · 12 sources
drugadalimumab24 co-mentions · 12 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?